|
Industry Experts, Medical
Specialists and Regulators Discuss
Monitoring and Evaluating Fetal Effects of Drug Exposure
May 1-3, 2006, Washington, DC
Registration
is available for this three-day CME seminar
 [external link]
The Drug Information Association (DIA) will host a meeting with
members of the scientific and academic community and officials from
the FDA and CDC (Centers for Disease Control and Prevention) to
review and discuss various aspects of drug development and
surveillance related to delineating fetal risks associated with drug
exposures during pregnancy. The meeting takes place May 1-3 at the
Washington Marriott Hotel, Washington, DC.
Panel discussions, presentations and questions and answers with
medical officers, drug safety risk managers, researchers, and
specialists from the FDA and CDC will
- explain basic embryogenesis and how drugs can cause birth
defects
- identify when a post-marketing pregnancy exposure registry is
indicated
- describe the impact of the Health Insurance Portability and
Accountability Act (HIPAA) and informed consent on pregnancy
exposure registry design
- explain international requirements and guidelines for
monitoring drug exposures during pregnancy
- describe what data bases and general registries currently
exist. Sessions will also include reproductive toxicology and
pre-marketing considerations and perspectives for the future
This program offers Continuing Medical Education Credits;
American Nurses Credentialing contact hours; Accreditation Council
for Pharmacy (ACPE) Education Hours; and International Association
for Continuing Education and Training (IACET) education units.
For program information and registration, please see
http://www.diahome.org/product/9347/06011.pdf
[external link]
For more information about the meeting, contact Joanne Wallace,
DIA’s program manager at (215) 442-6100, or
Joanne.Wallace@diahome.org.
 Back
to Top 
Back to Workshops
PDF requires the free Adobe
Acrobat Reader
Date created April 7, 2006 |
